PRESS RELEASE

IMPEDI_MED ANNOUNCES WALTON TAYLOR, M.D. AS MEDICAL DIRECTOR

ImpediMed Limited today announced the appointment of Walton A. Taylor, M.D. as ImpediMed’s first Medical Director. Dr. Taylor is a board certified surgeon with extensive experience in the diagnosis and treatment of breast cancer. He is a Fellow of the American College of Surgeons and member of the American Society of Breast Surgeons. Dr. Taylor is a graduate of Vanderbilt University and received his medical degree from the University of Texas Medical Branch at Galveston. He resides in Dallas, Texas, where he will continue his surgical practice as the Director of the Medical Edge Breast Cancer Program.

CEO Greg Brown said, “We are honoured and excited to have Dr. Taylor as Medical Director on our team. Dr. Taylor was among the first breast surgeons in the United States to use L-Dex® technology routinely in his clinical practice. He is a true believer in the benefit that early identification and treatment of lymphoedema can have on his patients’ quality of life.”

“I use the L-Dex test as a clinical tool to assess the lymphatics in all of my breast cancer patients. Lymphoedema has historically been under-diagnosed or mis-diagnosed in the US and as a result, has likely left many patients with a chronic, debilitating condition. Thanks to technologies like L-Dex and the research done by the NIH¹, surgeons can now simply clinically assess patients for the earliest signs of lymphoedema and start treatment and education earlier,” said Dr. Taylor.

“I’ve been using L-Dex in my practice now for over 18 months. It’s only a matter of time until this prospective management model becomes the new standard of care. The choice is really quite simple actually; physicians either continue to react to lymphoedema when it is already too late or we raise our level of vigilance and periodically assess our patients so treatment can begin at the earliest sign of disease. Thanks to L-Dex testing, four of my patients from the last year still enjoy a quality of life similar to that which preceded their cancer treatment. With increasingly early detection of breast cancer and more effective primary treatment, survivorship has become a big issue. L-Dex is all about survivorship.

“I am looking forward to working with ImpediMed and using my first-hand experience to help educate my colleagues treating breast and other cancers. It’s important for patients at risk of this devastating, life-long and chronic impairment and their health insurance providers to know about the clinical benefits of prospective L-Dex surveillance,” Dr Taylor added.
The National Institutes of Health (NIH) published in June 2008 landmark findings from a five year clinical investigation demonstrating the importance of early detection and intervention of lymphoedema. Numerous clinical trials published since have confirmed the importance of intervening at an early stage in the natural progression of lymphoedema to prevent its debilitating impact to patients.


ENDS

For further information contact:

Greg Brown ImpediMed CEO

T: 61-7-3860-3700
Mobile/Cell: +61408281127

L-Dex® is a trademark of ImpediMed Limited.

* L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity*.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Preoperative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit www.impedimed.com.